ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,970.84
-1.11%
Dow Jones
42,992.21
-0.77%
US Dollar vs MXN
20.3272
0.00%
Brent Oil
73.44
0.00%
Bitcoin
94,252.92
0.10%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Rhythm Pharmaceuticals Inc (RYTM)

  7. Rhythm Pharmaceuticals Inc (RYTM) Noticias

Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc (RYTM)

NASDAQ
55.59
-0.95
(-1.68%)
Cerrado 28 Diciembre 3:00PM
Delayed by 15 minutes
55.59
0.00
(0.00%)
Fuera de horario: 5:52PM
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

RYTM Noticias

Solo noticias oficiales

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
13 Noviembre 2024
RYTM (-1.68%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
13 Noviembre 2024
RYTM (-1.68%)

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
Edgar (US Regulatory)
13 Noviembre 2024
RYTM (-1.68%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
12 Noviembre 2024
RYTM (-1.68%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 Noviembre 2024
RYTM (-1.68%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
07 Noviembre 2024
RYTM (-1.68%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
06 Noviembre 2024
RYTM (-1.68%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
06 Noviembre 2024
RYTM (-1.68%)

Form 8-K - Current report
Edgar (US Regulatory)
05 Noviembre 2024
RYTM (-1.68%)

RYTM Discussion

Ver más
Monksdream Monksdream 2 meses hace
RYTM 10Q 11/5
👍️0
Monksdream Monksdream 3 meses hace
RYTM approaching a 52=week high
👍️0
Monksdream Monksdream 10 meses hace
RYTM new 52 week high
👍️0
Monksdream Monksdream 11 meses hace
RYTM new 52 week high

👍️0
Monksdream Monksdream 1 año hace
RYTM new 52 week high
👍️0
Monksdream Monksdream 1 año hace
RYTM new 52 week high
👍️0
midastouch017 midastouch017 2 años hace
In my view ORMP is better than RYTM from investment perspective.

Sigh, how wrong can one be!
(including me - of course)
👍️0
bandit007 bandit007 2 años hace
Why am I the only one posting here? This thing has been steady up over100% since I started posting here. Even on a day like today when most others are red. Another green day here!! $RYTM
👍️0
bandit007 bandit007 2 años hace
When $20 breaks and holds this will fly! IMO
👍️0
bandit007 bandit007 2 años hace
Looking like it’s ready to move up again here. Possible bounce off of support.
👍️0
Amatuer17 Amatuer17 2 años hace
Some you win some you lose - I had a lot of conviction but later lost faith after that time and sold completely.
👍️0
Laszlo1 Laszlo1 2 años hace
Sorry
👍️0
bandit007 bandit007 2 años hace
Thanks for posting. Breakout mode! GL
👍️0
conix conix 2 años hace
RYTM Chart

👍️0
bandit007 bandit007 2 años hace
I’m liking the chart on this one.
👍️0
willlbone willlbone 3 años hace
Two year slide continues.
👍️0
Amatuer17 Amatuer17 3 años hace
I lost money on RYTM and booked losses already.
👍️0
midastouch017 midastouch017 3 años hace
In my view ORMP is better than
RYTM from investment perspective.

Spot on!
👍️0
Amatuer17 Amatuer17 4 años hace
In my view ORMP is better than RYTM from investment perspective.

The current market capon $255 million allows it to be a 10 bagger ($2.55 B) - speciall that it has first in class product and huge unmet market.

RTYM also has first in class product with unmet needs but it is rare disease and not many outside US can afford
👍️0
Amatuer17 Amatuer17 4 años hace
Agree - it is good company
Will take time to make money but proof of product is there.

The valuation is fair at this point - upside maybe 50-70% by end of the year based on how they price and are able show sale.

The payment cycle with insurance will be key as the product is very high priced -
👍️0
fishhunter fishhunter 4 años hace
I started building a major position. And already a little green!
Quite the biotech soon last couple weeks= opportunity!
👍️0
Amatuer17 Amatuer17 4 años hace
For some reason it is tanking now -sale the news
👍️0
midastouch017 midastouch017 4 años hace
RYTM is not cheap as it has market cap of $832 million for pre-revenue biotech - so it is richly valued.


Are you kidding? You know what the mc is today?

Market Cap 1.737B

Since you introduced me to this company it has doubled
in price, if it was richly valued then, what is it now?

But this is besides my previous point - namely i 'missed'
the entry point.
👍️0
Amatuer17 Amatuer17 4 años hace
You can actually wait for some time and buy - this is a long term play
👍️0
midastouch017 midastouch017 4 años hace
I missed out this one!

👍️0
Amatuer17 Amatuer17 4 años hace
Just amazing results - they are starting new basket trials.

The product is approved for one indication so it is now label expansion - the pricing power is amazing. This should really take off. Is it next Alexion in terms of rare disease treatment and pricing power?
👍️0
Amatuer17 Amatuer17 4 años hace
Head the conf call - It was good call.

The results are much better that what PR said. Slide 14-15 shows correct numbers which were clarified by them.

Real numbers
Total patients - 31
Total BBS patients - 28
No of patients dropped - 4
Total no of patients relevant - 24

No of patients with 5%+ weight reduction - 16 = 67% that is double the number compared to combined number of 34.5%

No of patients who lost more than 10% weight - 11 out of 24 (45.8%)
Mean reduction - 14.5%

Compared to 1st approval which had few hundred population, BBS has 1000-1500 target population in US alone

This is large population for rare disease - @ $200k per year - this is a big market.

Also this is not a gene therapy - so drug is needed forever and it keeps the weight down.

Last point - All genes targeted in basket trial are in BBS category (strong or very strong relationship) so they think the basket trial results may be positive.

Cash enough till 2022. I think if stock goes down further, it will be good opportunity to buy - stock could give 50% returns from here in 6 months based on basket trial results.
👍️0
Amatuer17 Amatuer17 4 años hace
Phase 3 results - BBS stat significant -AL not

Market reaction is not good. Conf call will give more info

https://finance.yahoo.com/news/rhythm-pharmaceuticals-announces-positive-topline-120000038.html
👍️0
Amatuer17 Amatuer17 4 años hace
Finally - Approval

“Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™(setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency”

Another good news - voucher that they can sell or use for next approval

“With this approval, the FDA issued a Rare Pediatric Disease Priority Review Voucher (PRV) to Rhythm. The PRV can be redeemed to receive priority review for any subsequent marketing application or sold or transferred to other companies for their programs.”


https://finance.yahoo.com/news/rhythm-pharmaceuticals-announces-fda-approval-123000486.html
👍️0
grich1 grich1 4 años hace
That’s a big run with PDUFA being in November. I took some profit but still in the game and will buy 100% back if reversal. Outstanding shares only @ 44M and float 30M. PT @ $33.
👍️0
midastouch017 midastouch017 4 años hace
Good call!

👍️0
Amatuer17 Amatuer17 4 años hace
What is happening? Looks good
👍️0
midastouch017 midastouch017 4 años hace
Not so sure the last few years.

I am no US citizen, i would not like to comment
about US politics. We have enough political
unrest in my part of the globe, in Israel.

I’ve done enough DD on PSTI and RDHL

I was a heavy investor in PSTI, sold it all a few
weeks ago at a big loss, and not looking back.

RDHL, otoh is a serious company, i am sure it will
go places, high places that is.

As for RYTM, I have no funds at the moment, but
will start a position soon.

GLTY
👍️0
Amatuer17 Amatuer17 4 años hace
RYTM is not cheap as it has market cap of $832 million for pre-revenue biotech - so it is richly valued.

It has 70 employees - more than many biotech at this stage but not sufficient for marketing the drug. So they have to find a partner or go with buyout.

The good news is - the co has $228 milllion plus cash and it will allow them to run till end of 2021.

They are in niche area and there is no other competition nearby. If the drug can address genetic obesity - they have 80,000 target audience in US alone.

If the drug can be tested on genetic obesity/weight loss, it will be gold mine.
👍️0
pennyrich pennyrich 4 años hace
Not so sure the last few years. But what the heck.
I’m new on RYTM. I’ve done enough DD on PSTI and RDHL to hold a small 500 share stake in both. I’ll do some extra digging here because the stakes are much higher. The last 3 months haven’t been bad on the other two.
GLTUA
Pr
👍️0
midastouch017 midastouch017 4 años hace
Sure. A free country, isn't it?

👍️0
pennyrich pennyrich 4 años hace
Can anyone play???
👍️0
midastouch017 midastouch017 4 años hace
Thanks for the heads up Amatuer17,
i'll dig into it over the weekend.

👍️0
Amatuer17 Amatuer17 4 años hace
Welcome to the board. Hope we all make money

This is a PDUFA based play

PDUFA date - 27th Nov

Disease - rare disease - obesity based on genetics

MOA - impacts the MC4PA gene that controls obesity and hunger. They have 4 more trials for other sub areas also in advance stage.

As per conf call - they are looking at pricing from $200k to $400k per year Patient population for this approval - around 1000

https://ir.rhythmtx.com/static-files/fd4e0919-4d82-47e0-afe3-8cd9b5151490
👍️0

Su Consulta Reciente

NASDAQ
RYTM
Rhythm Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados